

ARES ALLERGY HOLDINGS PLC



COMBINATION OF STALLERGENES AND GREER LABORATORIES:

CREATION OF THE GLOBAL LEADER IN ALLERGY IMMUNOTHERAPY

London (United Kingdom), 8 September 2015 – Ares Allergy Holdings plc (“Ares Allergy”), announces that the merger of STALLERGENES and Ares Allergy took place today, marking the culmination of the project to combine STALLERGENES SA and GREER Laboratories Inc. (“GREER”) announced on 3 March 2015. By joining forces under Ares Allergy, STALLERGENES and GREER become the global leader¹ in allergy immunotherapy, with combined sales² of €312.5 million (USD 344 million) in 2014 and 1,434 employees.

The merger was approved by the shareholders of STALLERGENES and Ares Allergy at the general meetings of 26 June 2015 and 4 August 2015 respectively. In accordance with English law, the completion date of the merger was set by a ruling of the Chancery Division of the High Court of Justice at 8 September 2015.

Fereydoun Firouz, Chairman and Chief Executive Officer of Ares Allergy, said:

"Today our Group has taken a major step forward. By combining the assets of STALLERGENES and GREER, Ares Allergy has become the worldwide leader in the development and marketing of allergy immunotherapy treatments. Anchored by a strong foundation, we will develop additional innovative solutions for our customers and patients; expand the number of patients who benefit from allergy therapies; and generate strong returns for our shareholders. Our core growth strategy will be focused on investing in our marketed products, our R&D pipeline and targeted acquisitions. Ultimately, we aspire to enable people with allergies, globally, to live normal lives."

Ares Allergy will propose at a shareholders meeting to be convened in Q4 2015 the name change of Ares Allergy Holdings plc to Stallergenes Greer plc.

¹ According to internal estimates

² based on 2014 financial information

The exchange ratio that was approved by the STALLERGENES shareholders provides for the issuance of one new Ares Allergy share for each existing Stallergenes share (excluding treasury shares) held on 8 September 2015. Trading in STALLERGENES shares on Euronext Paris was suspended after the stock exchange closed on 7 September 2015. Ares Allergy shares will be admitted to trading on the Euronext Paris regulated market today, the date of completion of the merger, at 8:00 am (CET) and settlement and delivery of the shares will take place on September 10, 2015.

Trading information:

Name: Stallergenes Greer

ISIN: GB00BZ21RF93 1 - Ticker: STAGR

ICB classification: 4577

Market: Euronext Paris regulated market

ABOUT ARES ALLERGY HOLDINGS PLC

Headquartered in London (UK), Ares Allergy is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and provision of allergy immunotherapy products and services. Ares Allergy is the parent company of Greer Laboratories, Inc. (whose registered office is in the U.S.) and has become the parent company of STALLERGENES SA (whose registered office is in France) following completion of the merger of STALLERGENES SA with and into Ares Allergy.

Contact:

UK: Robin Wrench, Brunswick Group

Email: aresallergy@brunswickgroup.com

Tel. +44 (0)20 7404 5959

Forward-looking statements related to Ares Allergy Holdings plc

This press release may contain forward-looking statements concerning the proposed combination and the benefits expected. Such statements are based upon the current beliefs and expectations of Ares Allergy Holdings Plc's management and are subject to risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements, due to various factors. Without being exhaustive, such factors include economic situations and business conditions, including legal and product evaluation issues, fluctuations in currencies and demand, and changes in competitive factors. Ares Allergy Holdings Plc disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.

Restrictions:

This document cannot be released directly or indirectly in South Africa, Australia, Canada, Japan, New Zealand or the United States of America. The information contained in this document does not constitute an offer to sell or the solicitation of an offer to buy or sell shares or other financial instruments in Ares Allergy Holdings Plc or Stallergenes S.A. in any jurisdiction, in particular in any jurisdiction in which such an offer, solicitation, purchase or sale would be illegal prior to the registration, exemption from registration or other qualification under the terms of legislation on financial instruments in such a jurisdiction. Persons in possession of this document are required to inform themselves about and comply with these restrictions. Neither Stallergenes S.A., nor Ares Allergy Holdings Plc or any other party to this transaction mentioned in this document accepts any liability in respect of persons who have obtained this document in violation of these restrictions. Shares in Ares Allergy Holdings Plc have not been and will not be registered under the US Securities Act of 1933 or under any other legislation of any jurisdiction in the United States of America.

Not for release, directly or indirectly, in South Africa, Australia, Canada, Japan, New Zealand or the United States of America